CPT 6281
Alternative Names: CPT-6281; CT 01Latest Information Update: 11 Aug 2026
At a glance
- Originator Captor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action NEK7 protein modulators; Transcription factor degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Liver cancer; Lung cancer; Neuroendocrine tumours
Most Recent Events
- 02 Jun 2026 Pharmacodynamic and pharmacokinetic data from preclinical trial in Liver cancer presented at 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 17 Apr 2026 Pharmacodynamics data from a preclinical trial in Liver cancer presented at the 117th Annual Meeting of the American Association for Cancer Research 2026 (AACR-2026)
- 24 Jul 2025 Phase-I clinical trials in Liver cancer in Poland (PO) (Captor Therapeutics Pipeline, July 2025)